Skip to main content
. Author manuscript; available in PMC: 2015 Oct 1.
Published in final edited form as: Abdom Imaging. 2014 Oct;39(5):1027–1035. doi: 10.1007/s00261-014-0136-7

Figure 2.

Figure 2

A 68-year-old man with Gleason 3 + 3 prostate cancer, clinical stage T1c, PSA of 4.5 ng/mL. Follow-up transrectal ultrasound-guided biopsy performed 3 months after the MRI demonstrated Gleason 5 + 4 prostate cancer. A T2-weighted MRI shows a clear focus of low signal intensity in the peripheral zone of the right midgland gland (arrow). B Diffusion-weighted MRI shows a concordant abnormality with markedly reduced ADC (arrow). C MR spectroscopic imaging shows abnormal metabolism characterized by high choline and low citrate peaks in the region of the T2 abnormality (arrowheads).